Market research
ORGS Orgenesis Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 980K
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 3.35
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US68619K2042
- Market cap
- 980K
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 3.35
About
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ORGS discussion.
5 years, 4 months ago
Orgenesis Inc is currently in a long term downtrend where the price is trading 12.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.1.
Orgenesis Inc's total revenue sank by 74.7% to $2M since the same quarter in the previous year.
Its net income has dropped by 751.7% to $-52M since the same quarter in the previous year.
Finally, its free cash flow fell by 421.7% to $-45M since the same quarter in the previous year.
Based on the above factors, Orgenesis Inc gets an overall score of 1/5.